Cloud-Clone expands breast cancer biomarker panel for precision research

Cloud-Clone Corp. says it has built a breast cancer biomarker portfolio covering more than 30 core targets to support research from basic studies to clinical specimen testing. The company is highlighting the catalog as breast cancer research shifts toward precision medicine and as its reagents appear in high-profile publications.

Why it matters: - Breast cancer research increasingly depends on standardized biomarker detection to study tumor subtypes, drug resistance and treatment response. - Cloud-Clone is positioning its expanded reagent portfolio as a one-stop toolkit for labs working across basic, animal and clinical research. - The company says the broader panel could help support more precise oncology studies as targeted and antibody-drug conjugate therapies evolve.

What happened: - Cloud-Clone Corp. unveiled a breast cancer biomarker product matrix covering more than 30 core targets. - The portfolio includes recombinant proteins, specific antibodies, single-plex ELISA kits and multiplex detection panels. - The product line is designed for human, mouse, rat and other species. - The company tied the launch to the 2026 National Breast Cancer Conference and the release of the CSCO Breast Cancer Clinical Practice Guidelines. - Cloud-Clone says its products are aimed at supporting global breast cancer research from mechanism studies to clinical specimen testing.

The details: - The biomarker coverage includes BRCA1, BRCA2, EGFR, HER2, PARP and c-kit (SCFR). - The portfolio also covers Ki-67, MUC-1, uPA, PAI-1, TP53 and NM23-H1. - Additional targets include Nestin, Caveolin-1, RHAMM and CK14. - Cloud-Clone has pre-developed reagents for AIM2 and DUSP1 to support emerging research. - The company cited its DCA ELISA kit, Catalog No. CES089Ge, with a detection range of 12.35–1000 ng/mL and a limit of detection of 4.91 ng/mL. - Cloud-Clone said the DCA kit posted intra-assay CV below 10% and inter-assay CV below 12%. - The company holds ISO9001, ISO13485 and ISO14001 certifications. - Cloud-Clone said its controls run from raw-material traceability through finished-product release. - CiteAb has named Cloud-Clone one of the world’s best ELISA kit suppliers.

Between the lines: - Cloud-Clone is using publication validation to reinforce confidence in its reagents, a common strategy in research tools markets where credibility drives purchasing. - The company highlighted two papers as proof points: a May 2026 Cell Metabolism study from Zhejiang University and an April 2020 Nature Communications study from Wuhan University. - In the Cell Metabolism paper, researchers quantified serum deoxycholic acid in 56 samples using Cloud-Clone’s DCA ELISA kit. - In the Nature Communications study, researchers used Cloud-Clone MIP-1α and Histamine ELISA kits to characterize an anti-tumor nanovaccine. - Cloud-Clone also pointed to use by researchers at the Medical University of South Carolina, the Affiliated Hospital of Xuzhou Medical University, Nanjing University, the National Cancer Center Korea, the University of Würzburg and the University of Glasgow. - The company says multi-center trials have repeatedly validated the sensitivity, specificity and reproducibility of its reagents.

What's next: - Cloud-Clone says it will keep refining manufacturing workflows and expanding its biomarker catalog. - The company is aiming to become a preferred partner for breast cancer researchers and broader life science labs worldwide. - Cloud-Clone links the next phase of its business to continued demand for precise biomarker detection tools.

The bottom line: - Cloud-Clone is betting that breadth, quality controls and publication-backed validation will help its breast cancer assay lineup stand out in precision oncology research.